---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-155978"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:07:35.269289+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics appoints Dr. Charles Q. Morris as Chief Medical Officer effective April 20, 2026

## Summary
- Dr. Morris, age 61, brings over 30 years of oncology drug development experience; most recently CMO at Lava Therapeutics.
- Annual base salary of $535,000, target bonus of 40% of base, and option for 450,000 PRLD shares vesting over 4 years.
- Severance provides 9 months salary/benefits (or 12 months plus full bonus and equity acceleration in change-of-control context).
- Company highlights his role will be critical as lead programs in MPN and ER+ breast cancer enter clinical development in 2026.

## SEC filing metadata
- accession: 0001193125-26-155978
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526155978/0001193125-26-155978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526155978/prld-20260415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-155978
- JSON: https://secwatch.observer/filing/0001193125-26-155978.json
- Plain text: https://secwatch.observer/filing/0001193125-26-155978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.